AN2 Therapeutics Inc

Chart
Good to know: Investing in stocks tends to provide long-term positive returns, but it also involves risks. You can lose some or all of your investment. Past performance of this stock is not a reliable indicator of future results. Data from external providers has not been altered by Saxo. See full data disclaimer.
Quotes
- Bid
- Ask
- Open
- Previous close
- Volume
- Relative volume
- High
- Low
Returns
Key stats
ESG risk
ESG risk is a measure of how well a company manages material ESG risks. Sustainalytics’ ESG risk category is designed to help investors identify and understand financially material ESG risks at the company level and how they might affect the long-term performance for equity investments. The scale is from 0-100. The lower the risk, the better (0 is equivalent to no risk and 100 the most severe).
Download ESG risk methodology (PDF)Financials
About AN2 Therapeutics Inc
AN2 Therapeutics Inc is a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics derived from its boron chemistry platform. The company has a pipeline of boron-based compounds in development for Chagas disease, non-tuberculous mycobacterial (NTM) and melioidosis, along with early-stage programs focused on targets in infectious diseases and oncology.
Frequently asked questions
To buy AN2 Therapeutics Inc stock, open a Saxo account and fund it. With SaxoInvestor or SaxoTrader, you can easily search for AN2 Therapeutics Inc by name or ticker, choose the number of shares, and place your order.
The ticker symbol for AN2 Therapeutics Inc is ANTX:xnas. You can use this code to quickly find the stock in Saxo’s platforms and track its price and performance.
AN2 Therapeutics Inc has its primary listing on NASDAQ. You can trade AN2 Therapeutics Inc with a Saxo account, alongside thousands of other stocks worldwide.
Yes, AN2 Therapeutics Inc is available to trade on SaxoInvestor and SaxoTrader. You can buy shares directly and include AN2 Therapeutics Inc as part of a broader investment portfolio.